SynthesisFrontiers in immunology2026
Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas are characterized by an aggressive course and a very poor prognosis. Due to the limited benefit of immunotherapy in patients with HER2-negative tumors, new therapeutic targets are sought. Zolbetuximab is a chimeric monoclonal antibody targeting the CLDN18.2 protein, which is overexpressed in 50-80% of gastric cancers. Materials and methods: This review is based on phase I-III clinical trials, including the pivotal SPOTLIGHT, GLOW, FAST, and ILUSTRO trials. The efficacy and safety of zolbetuximab in combination with chemotherapy were assessed as first-line treatment for adults with locally advanced or metastatic G/GEJ adenocarcinoma, HER2-negative, and highly CLDN18.2-expressing. Results: Early phase studies confirmed the clinical activity and tolerability of zolbetuximab. A Japanese phase I study demonstrated the safety and pharmacokinetic profile of zolbetuximab as monotherapy, establishing the recommended dose in subsequent studies. The phase II FAST study demonstrated that the addition of zolbetuximab to EOX chemotherapy significantly improved both PFS (HR 0.44; p=0.0005) and OS (HR 0.55; p=0.0001). The phase II ILUSTRO study demonstrated activity of zolbetuximab both as monotherapy (ORR 9%) and in combination with mFOLFOX6 (ORR 39%), supporting its advancement to phase III. These results were confirmed in two pivotal randomized phase III studies. In the SPOTLIGHT study, the addition of zolbetuximab to mFOLFOX6 reduced the risk of death by 25% (median OS 18.23 vs. 15.54 months), and in the GLOW study, the addition of zolbetuximab to CAPOX reduced the risk of death by almost 23% (median OS 14.39 vs. 12.16 months). The most common adverse events were nausea and vomiting, occurring primarily in the first treatment cycle. Conclusions: Zolbetuximab represents a significant advancement in the treatment of patients with advanced G/GEJ adenocarcinoma overexpressing CLDN18.2, addressing an important unmet clinical need. However, optimizing the stringent threshold for CLDN18.2 positivity (requiring staining in ≥75% of cells) and establishing a treatment regimen for patients with concurrent CLDN18.2 and PD-L1 expression remains a significant challenge. The review protocol was prospectively registered in the PROSPERO database (International Prospective Register of Systematic Reviews) under registration number CRD420261383764. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261383764.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.